Artisan Partners Asset Management Inc (NYSE:APAM) is expected to pay $0.56 on Feb 28, 2019. (NYSE:APAM) shareholders before Feb 13, 2019 will receive the $0.56 dividend. Artisan Partners Asset Management Inc’s current price of $25.28 translates into 2.22% yield. Artisan Partners Asset Management Inc’s dividend has Feb 14, 2019 as record date. Feb 5, 2019 is the announcement. The stock increased 2.39% or $0.59 during the last trading session, reaching $25.28. About 423,568 shares traded. Artisan Partners Asset Management Inc. (NYSE:APAM) has declined 37.87% since February 12, 2018 and is downtrending. It has underperformed by 37.87% the S&P500. Some Historical APAM News: 20/03/2018 – ARTISAN PARTNERS HOLDS 5.01% OF GBL AS OF MARCH 14; 11/03/2018 – CATELLA STRENGTHENS IN PACT TO BUY MAJORITY STAKE IN APAM LTD; 10/04/2018 – ARTISAN PARTNERS ASSET MANAGEMENT MARCH AUM $114.8B; 11/04/2018 – PANALPINA SHAREHOLDER ARTISAN CRITICIZES COMPANY LEADERSHIP: HZ; 01/05/2018 – Artisan Partners Asset Management Inc. Reports 1Q18 Results; 20/04/2018 – DJ Artisan Partners Asset Management , Inst Holders, 1Q 2018 (APAM); 08/03/2018 Artisan Partners Wins CAMRADATA Asset View Awards; 01/05/2018 – ARTISAN 1Q ADJ EPS 78C, EST. 73C; 10/04/2018 – ARTISAN PARTNERS ASSET MANAGEMENT INC – ARTISAN FUNDS AND ARTISAN GLOBAL FUNDS ACCOUNTED FOR $57.9 BLN OF TOTAL AUM AS OF MARCH 31; 17/04/2018 – Artisan Partners Asset Management Inc. to Announce 1Q18 Results on May 1, 2018
Inflarx N.V. (NASDAQ:IFRX) had a decrease of 1.57% in short interest. IFRX’s SI was 231,600 shares in February as released by FINRA. Its down 1.57% from 235,300 shares previously. With 11,900 avg volume, 20 days are for Inflarx N.V. (NASDAQ:IFRX)’s short sellers to cover IFRX’s short positions. The SI to Inflarx N.V.’s float is 3.2%. The stock increased 0.45% or $0.15 during the last trading session, reaching $33.65. About 44,272 shares traded. InflaRx N.V. (NASDAQ:IFRX) has risen 63.49% since February 12, 2018 and is uptrending. It has outperformed by 63.49% the S&P500. Some Historical IFRX News: 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Nasdaq.com which released: “InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa – Nasdaq” on February 06, 2019, also Nasdaq.com with their article: “Wessanen Q4/ FY 2018 results: Moderate growth and improved profitability – Nasdaq” published on February 12, 2019, Nasdaq.com published: “Notice Regarding Voluntary Adoption of International Financial Reporting Standards (IFRS) – Nasdaq” on February 07, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “International Petroleum Corporation 2018 Year-End Financial Results and 2019 Budget, Production and Resource Guidance – Nasdaq” published on February 12, 2019 as well as Nasdaq.com‘s news article titled: “Flow Capital Announces 2018 Year End and Fourth Quarter Results – Nasdaq” with publication date: February 11, 2019.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $863.53 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
Artisan Partners Asset Management Inc. is publicly owned investment manager. The company has market cap of $1.95 billion. It provides its services to pension and profit sharing plans, trusts, endowments, foundations, charitable organizations, government entities, private funds and non-U.S. funds, as well as mutual funds, non-U.S. funds and collective trusts. It has a 7.81 P/E ratio. It manages separate client-focused equity and fixed income portfolios.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.